CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM048802
035-os BibID:PMID:24163303
Első szerző:Hunyadi János (bőrgyógyász, kozmetológus, allergológus)
Cím:Autologous Dendritic Cell Based Adoptive Immunotherapy of Patients with Colorectal Cancer : a phase I-II study / János Hunyadi, Csilla András, Imre Szabó, János Szántó, Kornélia Szluha, Sándor Sipka, Péter Kovács, Attila Kiss, Gyula Szegedi, István Altorjay, Péter Sápy, Péter Antal-Szalmás, László Tóth, György Fazekas, Éva Rajnavölgyi
Dátum:2014
ISSN:1219-4956 1532-2807
Megjegyzések:Dendritic cell-based active immunotherapies of cancer patients are aimed to provoke the proliferation and differentiation of tumor-specific CD4+ and CD8+ T-lymphocytes towards protective effector cells. Isolation and in vitro differentiation of circulating blood monocytes has been established a reasonable platform for adoptively transferred DC-based immunotherapies. In the present study the safety and tolerability of vaccination by autologous tumor cell lysates (oncolysate)- or carcinoembriogenic antigen (CEA)-loaded DCs in patients with colorectal cancer was investigated in a phase I-II trial. The study included 12 patients with histologically confirmed colorectal cancer (Dukes B2-C stages). Six of the patients received oncolysate-pulsed, whereas the other six received recombinant CEA-loaded autologous DCs. The potential of the tumor antigen-loaded DCs to provoke the patient's immune system was studied both in vivo and in vitro. The clinical outcome of the therapy evaluated after 7 years revealed that none of the six patients treated with oncolysate-loaded DCs showed relapse of colorectal cancer, whereas three out of the six patients treated with CEA-loaded DCs died because of tumor relapse. Immunization with both the oncolysate- and the CEA-loaded autologous DCs induced measurable immune responses, which could be detected in vivo by cutaneous reactions and in vitro by lymphocyte proliferation assay. Our results show that vaccination by autologous DCs loaded with autologous oncolysates containing various tumor antigens represents a well tolerated therapeutic modality in patients with colorectal cancer without any detectable adverse effects. Demonstration of the efficacy of such therapy needs further studies with increased number of patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Pathology & Oncology Research. - 20 : 2 (2014), p. 357-365. -
További szerzők:András Csilla (1961-) (onkológus szakorvos) Szabó Imre Szántó János (1949-) (onkológus szakorvos) Szluha Kornélia (1955-) (radioterapeuta, radiológus, szülész-nőgyógyász, onkológus) Sipka Sándor (1945-) (laboratóriumi szakorvos) Kovács Péter (1947-) (belgyógyász, kardiológus, klinikai farmakológus) Kiss Attila (1942-) (belgyógyász, haematológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Sápy Péter (1942-) (sebész) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Tóth László (1971-) (patológus) Fazekas György Rajnavölgyi Éva (1950-) (immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM033820
Első szerző:Szántó János (onkológus szakorvos)
Cím:Secretory breast cancer in a 7.5-year old boy / Szántó, J., András, C., Tsakiris, I., Gomba, S., Szentirmay, Z., Bánlaki, S., Szilágyi, I., Kiss, C., Antall, P., Horváth, Á., Lengyel, L., Castiglione-Gertsch, M.
Dátum:2004
ISSN:0960-9776
Megjegyzések:Breast cancer is extremely rare in children, and consequently no consensus has been reached on the optimal treatment modalities. The medical history and treatment plan for a 7.5-year old male breast cancer patient is described. Radical mastectomy with sentinel node biopsy was performed in October 2002. As no malignant cells were detected in the sentinel node, and no BRCA1-2 mutations were detected, no further radio- or chemotherapy was performed. A "wait-and-see" policy was decided on. Further treatment will be given if this becomes necessary with the development of metastases.
Tárgyszavak:Orvostudományok Klinikai orvostudományok esettanulmány
egyetemen (Magyarországon) készült közlemény
Megjelenés:Breast 13 : 5 (2004), p. 439-442. -
További szerzők:András Csilla (1961-) (onkológus szakorvos) Tsakiris, Ioannis (1976-) (orvos) Gomba Szabolcs (1933-2016) (pathológus) Szentirmay Zoltán Bánlaki Szidónia Szilágyi I. Kiss Csongor (1956-) (hematológus, onkológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Horváth Ákos (1944-) (onkoradiológus) Lengyel L. Castiglione-Gertsch, Monica
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM040289
Első szerző:Szekanecz Éva (onkológus szakorvos)
Cím:Malignancies and soluble tumor antigens in rheumatic diseases / Szekanecz E., András C., Sándor Z., Antal-Szalmás P., Szántó J., Tamási L., Kiss E., Szekanecz Z.
Dátum:2006
ISSN:1568-9972
Megjegyzések:Paraneoplastic symptoms, caused by a malignancy, but not directly related to invasion by the tumor or its metastases are the result of a wide variety of tumor-derived biologic mediators like hormones, peptides, antibodies, cytotoxic lymphocytes, autocrine and paracrine mediators. Recognition of paraneoplastic syndromes is important, as it may lead to an early diagnosis of cancer. There is some evidence that systemic inflammatory diseases, such as rheumatoid arthritis (RA), lupus, scleroderma or dermatomyositis may increase the risk for the development of malignancies, predominantly lymphoproliferative disorders. However, reports are somewhat controversial. Immunosuppressive and cytotoxic drugs used in antirheumatic therapy, such as methotrexate, cyclophosphamide, azathioprine or anti-TNF biologicals may also lead to the development of such tumors. Tumor-associated antigens may be produced by inflammatory cells and their production may be increased in RA and other autoimmune diseases.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Autoimmunity Reviews. - 6 : 1 (2006), p. 42-47. -
További szerzők:András Csilla (1961-) (onkológus szakorvos) Sándor Zsuzsa (1980-) (pathológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Szántó János (1949-) (onkológus szakorvos) Tamási László Kiss Emese (1960-) (belgyógyász, immunológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM006180
Első szerző:Szekanecz Éva (onkológus szakorvos)
Cím:Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus : associations with organ manifestations, immunolaboratory markers and disease activity indices / Éva Szekanecz, Gabriella Szűcs, Zoltán Szekanecz, Tünde Tarr, Péter Antal-Szalmás, Szilvia Szamosi, János Szántó, Emese Kiss
Dátum:2008
Megjegyzések:Some tumor-associated antigens (TAAs) are expressed on inflammatory cells. We previously detected increased production of CA15-3, CA19-9 and CA125 in rheumatoid arthritis (RA). The production of some TAAs may also be increased in patients with systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and other connective tissue diseases. Some of these TAAs contain sialylated carbohydrate motifs and they are involved in tumor-associated cell adhesion and metastasis. OBJECTIVES: We assessed levels of TAAs in the sera of SSc, SLE patients, patients with infectious diseases and healthy subjects. Serum TAA levels were correlated with each other, as well as with disease activity markers and organ involvement. METHODS: TAAs including CEA, CA15-3, CA72-4, CA125 and CA19-9 were assessed by immunoassay in the sera of 92 patients with SSc, 40 patients with SLE, 50 age- and sex-matched healthy controls, as well as with 40 patients with current bacterial or viral infections. Normal upper limits for these TAAs were 3.4 mg/l, 25 kU/l, 6.9 kU/l, 35 kU/l and 34 kU/l, respectively. RESULTS: There were significantly more SSc patients showing abnormally high levels of CA19-9 (8.8% vs 2.0%), CA125 (11.0% vs 6.0%) and CA15-3 (28.4% vs 14.0%) in comparison to controls (p < 0.05). In SLE, significantly more patients had elevated levels of CEA (32.5% vs 20.0%), CA19-9 (7.5% vs 2.0%), CA125 (15.0% vs 6.0%) and CA72-4 (15.0% vs 8.0%) than did controls (p < 0.05). The mean absolute serum levels of CEA (6.6+/-1.7 vs 1.8+/-1.4 mg/l) and CA15-3 (22.9 +/- 1.8 vs 18.6 +/- 2.2 kU/l) were also significantly higher in SSc compared to controls (p < 0.05). We found numerous correlations between the serum levels of different TAAs within the SSc and SLE population. Among SSc patients, serum CEA (R = 0.290; p = 0.005), CA15-3 (R = 0.260; p = 0.020) and CA19-9 (R = 0.257; p = 0.013) correlated with renal involvement. Serum CA15-3 also correlated with joint involvement (R = 0.329; p = 0.003), ANA positivity (R = 0.288; p = 0.010) and CRP levels (R = 0.407; p < 0.001). Within the SLE population, serum CA72-4 correlated with central nervous involvement (R = 0.624; p = 0.004) and CA125 correlated with the SLEDAI composite activity index (R = 0.666; p = 0.002). Patients with infections exerted serum TAA patterns similar to healthy controls. CONCLUSION: The concentration of some TAAs may be elevated in the sera of patients with SSc or SLE in comparison to healthy subjects. Pathogenically, most of these TAAs contain carbohydrate motifs and thus they may be involved in inflammation-associated adhesive events. Furthermore, the production of some TAAs may correlate with organ involvement or disease activity in scleroderma or lupus.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal of Autoimmunity. - 31 : 4 (2008), p. 372-376. -
További szerzők:Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Szamosi Szilvia (1975-) (belgyógyász, reumatológus) Szántó János (1949-) (onkológus szakorvos) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:elektronikus változat
DOI
Borító:

5.

001-es BibID:BIBFORM001945
Első szerző:Szekanecz Éva (onkológus szakorvos)
Cím:Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis : potential adhesion molecules in synovial inflammation? / Szekanecz E., Sándor Z., Antal-Szalmás P., Soós L., Lakos G., Besenyei T., Szentpétery A., Simkovics E., Szántó J., Kiss E., Koch A. E., Szekanecz Z.
Dátum:2007
Megjegyzések:Some tumor-associated antigens (TAAs) are expressed on inflammatory cells. We previously detected carcinoembryonic antigen (CEA; CD66) in the rheumatoid (RA) synovium. The production of CEA, CA19-9, CA125, and CA15.3, may be increased in patients with RA, scleroderma, lupus, and Sjogren's syndrome (SS). Some of these TAAs contain sialylated carbohydrate motifs and they are involved in tumor-associated cell adhesion and metastasis. We assessed levels of TAAs in the sera of RA patients and healthy subjects. Serum TAA levels were correlated with disease markers including serum rheumatoid factor (RF), C-reactive protein (CRP), and anti-CCP antibody levels, DAS28, age disease duration. TAAs including CEA, CA15-3, CA72-4, CA125, and CA19-9, and neuron-specific enolase (NSE) were assessed by immunoassay in the sera of 75 patients with RA and 50 age- and sex-matched healthy controls. Normal upper limits for these TAAs were 3.4 microg/L, 25 kU/L, 6.9 kU/L, 35 kU/L, 34 kU/L, and 16.3 microg/L, respectively. There were significantly more RA patients showing abnormally high levels of CA125 (10.8% versus 7.1%), CA19-9 (8.1% versus 0%), and CA15-3 (17.6% versus 14.3%) in comparison to controls (P < 0.05). The mean absolute serum levels of CA125 (23.9 +/- 1.8 versus 16.8 +/- 2.2 kU/L) and CA19-9 (14.2 +/- 1.2 versus 10.5 +/- 1.6 kU/L) were also significantly higher in RA compared to controls (P < 0.05). Among RA patients, serum CEA showed significant correlation with RF (r = 0.270; P < 0.05). None of the assessed TAAs showed any correlation with CRP, anti-CCP, DAS28, age or disease duration. The concentration of some TAAs may be elevated in the sera of patients with established RA in comparison to healthy subjects. CEA, CA19-9, CA125, and CA15-3 contain carbohydrate motifs and thus they may be involved in synovitis-associated adhesive events. Furthermore, some TAAs, such as CEA, may also correlate with prognostic factors, such as serum RF levels.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
rheumatoid arthritis
tumor antigens
anti-CCP antibody
rheumatoid factor
carcinoembryonic antigen
Megjelenés:Annals of the New York Academy of Sciences 1108 (2007), p. 359-371. -
További szerzők:Sándor Zsuzsa (1980-) (pathológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Soós Lilla Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Besenyei Tímea (1980-) (reumatológus, belgyógyász) Szentpétery Ágnes (1978-) (reumatológus) Simkovics Enikő Szántó János (1949-) (onkológus szakorvos) Kiss Emese (1960-) (belgyógyász, immunológus) Koch, Alisa E. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:elektronikus változat
DOI
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.